Global menu

Our global pages

Magdalena Anna Kotyrba, Senior Associate

Magdalena Anna Kotyrba

Senior Associate



German, English, Polish

Practice areas

  • Competition, EU and Trade
  • Health and life sciences
  • Intellectual property
  • Regulatory investigations and enforcement
  • Technology

Practice notes

Magdalena Anna Kotyrba is a Senior Associate in Eversheds Sutherland’s Munich office and member both of its IP practice and the Health and Life Sciences Sector Group.

Her scope of activity includes the protection and enforcement of her clients’ IP rights, as well as advising clients on all kind of contracts related to the creation and exploitation of IP rights. Her clients are inter alia from the wholesale sector, from consumer goods and chemistry industry.

As member of our Health and Life Sciences Sector Group Magdalena advises companies from the life sciences industry on several areas and topics, including contractual as well as regulatory issues, topics related to clinical and other trials, as well as question related to healthcare compliance. She also advices her clients on questions in connection with manufacturing and distribution of products. Furthermore, she focuses on healthcare compliance subjects and works on technology agreements and convergence issues, such as apps in healthcare.

An important part of Magdalena’s activity is advising clients from the life sciences sector on topics related to R&D in general, but in particular regarding the creation and protection of IP rights in trials and collaborations between industry partners but also between the industry and universities or other research institutions, as well an on the transfer and/or exchanges of related rights such as licensing, technology transfer and in general IP-topics of all kinds.

Before joining Eversheds Sutherland, Magdalena worked for a boutique law firm focusing on pharmaceutical and competition law as well as in-house for an international pharmaceutical company in the area of R&D and healthcare compliance.

Magdalena's recent experience:

  • A US based technology group on the market access under CE-certification of a testing device in Europe
  • Otsuka on a licensing agreement with global pharmaceutical company Mylan to commercialize Deltyba™ (delamanid) for the treatment of adults with pulmonary multidrug-resistant tuberculosis (MDR-TB) in low- and middle-income countries
  • Owens & Minor on its sell of Movianto from a regulatory perspective (marketing authorizations and other licenses required)
  • An international generic drug company on the defence of marketing authorizations being challenged by the originator pharmaceutical company due to alleged IP infringements in the generics application
  • German research institution on IP and regulatory related topics in collaborations and trial agreements with research companies
  • INEOS on the production of disinfectants in response to the Covid-19 crisis
  • US based medical device manufacturer on IP related topics in pre- and post-CE-marketing trials
  • Otsuka on the First-of-its-kind global Collaboration with the Gates Foundation and Johnson & Johnson, GSK and Evotec to develop transformative treatment regimens for Tuberculosis
  • Medical devices distributor commercializing the Japanese parent company’s medical app to healthcare institutions in Europe, the Middle East and Africa
  • European based generics company on license agreements and collaborations
  • An US based medical device manufacturer on the negotiations of clinical trial agreements and post-CE-marketing trials agreement with universities and other German research institutions
  • An international pharmaceutical company on legal matters in connection with market access programs by several national regulators regarding pharmaceuticals against an infectious disease
  • International research company on R&D-collaborations and negotiations with research institutes and universities on development and licensing of new technologies
  • Otsuka on a licensing agreement with Russian pharmaceutical company R-Pharm to commercialize Deltyba™ (delamanid) for the treatment of adults with pulmonary multidrug-resistant tuberculosis (MDR-TB) in the Russian Federation and the Commonwealth of Independent States (CIS)

Featured article

Deutsches Profil